Structure-activity relationships for inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone lung tumorigenesis by arylalkyl isothiocyanates in A/J mice. 1991

M A Morse, and K I Eklind, and S S Hecht, and K G Jordan, and C I Choi, and D H Desai, and S G Amin, and F L Chung
Division of Chemical Carcinogenesis, Naylor Dana Institute for Disease Prevention, American Health Foundation, Valhalla, New York 10595.

Phenethyl isothiocyanate (PEITC), 3-phenylpropyl isothiocyanate (PPITC), 4-phenylbutyl isothiocyanate (PBITC), and the newly synthesized 5-phenylpentyl isothiocyanate (PPeITC), 6-phenylhexyl isothiocyanate (PHITC), and 4-(3-pyridyl)butyl isothiocyanate (PyBITC) were tested for their abilities to inhibit tumorigenicity and DNA methylation induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in the lungs of A/J mice. Mice were administered isothiocyanates by gavage for 4 consecutive days at doses of 5, 1, or 0.2 mumol/day prior to administration of 10 mumol of NNK by i.p. injection. Mice were sacrificed 16 weeks after NNK administration and pulmonary adenomas were quantitated, PEITC effectively inhibited NNK-induced lung tumors at a dose of 5 mumol/day but was not inhibitory at doses of 1 or 0.2 mumol/day. PPITC, PBITC, PPeITC, and PHITC were all considerably more potent inhibitors of NNK lung tumorigenesis than PEITC. While virtually no differences in inhibitory activity could be ascertained for PPITC, PBITC, and PPeITC, PHITC appeared to be the most potent tumor inhibitor of all of the compounds. At a dose of 0.2 mumol/day, PHITC pretreatment reduced tumor multiplicity by 85%. PyBITC, an analogue of both NNK and PBITC, was ineffective as an inhibitor. Using the same protocol, the compounds were found to have qualitatively similar inhibitory effects on NNK-induced DNA methylation when administered at 1 mumol/day. These results extend our previous findings that increased alkyl chain length enhances the inhibitory activity of an arylalkyl isothiocyanate toward NNK lung tumorigenesis and demonstrate the exceptional chemopreventive potentials of two new isothiocyanates, PPeITC and PHITC.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D009602 Nitrosamines A class of compounds that contain a -NH2 and a -NO radical. Many members of this group have carcinogenic and mutagenic properties. Nitrosamine
D003314 Corn Oil Oil from ZEA MAYS or corn plant. Maize Oil,Lipomul,Corn Oils,Lipomuls,Maize Oils,Oil, Corn,Oil, Maize,Oils, Corn,Oils, Maize
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013861 Thiocyanates Organic derivatives of thiocyanic acid which contain the general formula R-SCN. Rhodanate,Rhodanates
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

M A Morse, and K I Eklind, and S S Hecht, and K G Jordan, and C I Choi, and D H Desai, and S G Amin, and F L Chung
August 1994, Cancer research,
M A Morse, and K I Eklind, and S S Hecht, and K G Jordan, and C I Choi, and D H Desai, and S G Amin, and F L Chung
November 1990, Cancer research,
M A Morse, and K I Eklind, and S S Hecht, and K G Jordan, and C I Choi, and D H Desai, and S G Amin, and F L Chung
September 2009, Lung cancer (Amsterdam, Netherlands),
M A Morse, and K I Eklind, and S S Hecht, and K G Jordan, and C I Choi, and D H Desai, and S G Amin, and F L Chung
December 1997, Carcinogenesis,
M A Morse, and K I Eklind, and S S Hecht, and K G Jordan, and C I Choi, and D H Desai, and S G Amin, and F L Chung
April 1998, Carcinogenesis,
M A Morse, and K I Eklind, and S S Hecht, and K G Jordan, and C I Choi, and D H Desai, and S G Amin, and F L Chung
October 1991, Cancer research,
M A Morse, and K I Eklind, and S S Hecht, and K G Jordan, and C I Choi, and D H Desai, and S G Amin, and F L Chung
April 1992, Cancer research,
M A Morse, and K I Eklind, and S S Hecht, and K G Jordan, and C I Choi, and D H Desai, and S G Amin, and F L Chung
April 2003, Cancer letters,
M A Morse, and K I Eklind, and S S Hecht, and K G Jordan, and C I Choi, and D H Desai, and S G Amin, and F L Chung
November 2008, Cancer prevention research (Philadelphia, Pa.),
Copied contents to your clipboard!